SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
CareTrust REIT issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, reporting net income of $89.0 million ($0.38 per diluted share), Normalized FFO of $119.7 million ($0.51 per share), and Normalized FAD of $118.5 million ($0.51 per share), along with updated 2026 full-year guidance.
View raw filing on EDGAR →BARK issued a press release on August 6, 2026 announcing its financial results for fiscal first quarter ended June 30, 2026, disclosing revenue of $78.8 million (down 23.4% YoY), net income of $0.75 million (vs. prior year loss of $7.0 million), and Adjusted EBITDA of $0.6 million. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial statements, segment results, and forward guidance for Q2 and full-year fiscal 2027.
View raw filing on EDGAR →Globus Medical issued a press release on August 6, 2026 reporting its sales and operating results for the three and six month periods ended June 30, 2026. The disclosure includes net sales of $789.6 million (5.9% increase), GAAP net income of $151.6 million, GAAP diluted EPS of $1.10, and non-GAAP diluted EPS of $1.34 (55.8% increase), along with updated 2026 guidance for non-GAAP fully diluted EPS. This is a standard quarterly earnings release with consolidated financial statements and management commentary, clearly falling under Item 2.02 Results of Operations and Financial Condition.
View raw filing on EDGAR →Red Cat Holdings issued a press release on August 6, 2026 disclosing its financial results for the quarter ended June 30, 2026 (Q2 2026), including revenue of $20.2 million (527% Y/Y growth), gross profit of $3.3 million, and gross margin of 16.1%. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes condensed consolidated financial statements and is material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →Abacus Global Management disclosed Q2 2026 financial results with record total revenue of $73.0 million (up 30% year-over-year), adjusted net income of $27.1 million, and adjusted EPS of $0.28, along with forward guidance for Q3 2026 and full-year 2026.
View raw filing on EDGAR →James Hardie released first quarter FY27 earnings on August 6, 2026, disclosing net sales of $1.475 billion (up 64% YoY), net income of $104 million, and adjusted EBITDA of $422 million, all exceeding original guidance. The company also raised full-year FY27 outlook for pro forma sales growth and adjusted EBITDA growth. This is a standard quarterly earnings release with updated forward guidance, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →Nature's Sunshine Products issued a press release on August 6, 2026 announcing Q2 2026 financial results, including net sales of $117.0 million (up 2%), gross profit margin of 73.7% (up 194 basis points), GAAP net income of $3.5 million or $0.19 per diluted share, and adjusted EBITDA of $11.3 million.
View raw filing on EDGAR →Chesapeake Utilities issued a press release on August 6, 2026 announcing Q2 2026 financial results with net income of $25.4 million ($1.05 diluted EPS) and year-to-date results of $84.7 million ($3.51 diluted EPS), along with a presentation for the August 7, 2026 conference call.
View raw filing on EDGAR →Octave Specialty Group issued a press release on August 6, 2026, announcing financial results for the second quarter ended June 30, 2026. The disclosure includes detailed quarterly revenue ($83.0 million, up 51% YoY), net loss to shareholders of $(14.4) million, and segment-level performance metrics. This is a standard earnings release filed under Item 2.02, with the press release incorporated as Exhibit 99.1.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 financial results for Sanuwave Health, Inc. The press release announces revenue of $9.7 million (down 3% YoY), a net loss of $0.7 million (versus net income of $0.6 million in Q2 2025), and operating loss of $0.3 million (versus operating income of $1.4 million in Q2 2025). The company also withdrew its previously issued fiscal year 2026 guidance due to market conditions and Medicare reimbursement developments. This is material as it discloses significant deterioration in profitability and guidance withdrawal.
View raw filing on EDGAR →Ready Capital Corporation issued an earnings release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, with the press release attached as Exhibit 99.1. The disclosure includes GAAP loss per common share of $(0.63), distributable loss per common share of $(0.47), balance sheet metrics, portfolio information, and detailed consolidated financial statements. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Ellington Financial Inc. issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing net income of $54.4 million ($0.43 per share), adjusted distributable earnings of $75.5 million ($0.60 per share), and book value per share of $13.61.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02. The press release discloses comprehensive financial results including revenue of $652.5 million, net loss of $28.4 million, Adjusted EBITDA of $28.1 million, and updated 2026 guidance raising revenue to $2.6–$2.7 billion and tightening Adjusted EBITDA to $120–$135 million. The filing includes consolidated statements of operations and balance sheets, making this a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →Cable One issued a press release on August 6, 2026 disclosing its financial and operating results for the second quarter ended June 30, 2026. The filing includes detailed revenue, net loss, EBITDA, and cash flow metrics for Q2 2026 versus Q2 2025, along with a summary of key operational and financial developments. This is a standard quarterly earnings release disclosure under Item 2.02, with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →Roivant issued a press release on August 6, 2026, announcing its financial results for the fiscal quarter ended June 30, 2026, disclosing consolidated financial statements including revenue, operating expenses, net loss of $290.6 million, and cash position of $3.9 billion. The filing explicitly states this is Item 2.02 Results of Operations and Financial Condition with the press release attached as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →Health Catalyst issued a Q2 2026 earnings release on August 6, 2026 disclosing financial results for the quarter ended June 30, 2026, including revenue of $70.5M, net loss of $40.5M, and Adjusted EBITDA of $9.9M, along with forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →Planet Fitness issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $365.2 million (up 7.1%), net income of $67.1 million ($0.87 per diluted share), and Adjusted EBITDA of $152.8 million. The Item 2.02 disclosure explicitly states the press release is being furnished as Exhibit 99.1 and incorporated by reference, which is the standard format for earnings releases under Item 2.02 of Form 8-K.
View raw filing on EDGAR →Peloton disclosed its quarterly and full-year financial results for the period ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes Q4 and FY2026 revenue ($608M and $2.446B respectively), net income ($62M and $63M), Adjusted EBITDA ($142M and $468M), and forward guidance for Q1 and FY2027. This is a standard earnings release under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →This is a clear earnings release disclosing Voyager's second quarter 2026 financial results, including collaboration revenue ($3.2M), R&D expenses ($22.0M), G&A expenses ($7.5M), net loss ($24.5M), and cash position ($148.8M with runway into 2028). The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the company "announced second quarter 2026 financial results and corporate updates." The disclosure includes both financial statements (consolidated balance sheet and statement of operations) and material operational milestones (VY7523 and VY1706 clinical data expected Q4 2026).
View raw filing on EDGAR →vTv Therapeutics issued a press release on August 6, 2026, announcing financial results for the fiscal period ended June 30, 2026, including condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $13.1 million, cash position of $86.6 million) and six-month results. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway through anticipated clinical trial data readout.
View raw filing on EDGAR →CPI Card Group Inc. issued a press release on August 6, 2026, announcing Q2 2026 financial results with revenue of $149.2 million (15% increase), net income of $2.0 million (294% increase), and Adjusted EBITDA of $24.1 million (7% increase), along with raised 2026 guidance for revenue growth and Free Cash Flow.
View raw filing on EDGAR →WillScot issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including revenue of $612 million, net income of $47 million, and Adjusted EBITDA of $228 million, along with a raised full-year 2026 outlook. This is a standard quarterly earnings release disclosure under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Atlassian disclosed quarterly and fiscal year 2026 financial results, reporting Q4 revenue of $1,766 million (up 28% YoY), cloud revenue of $1,213 million (up 31% YoY), subscription ARR of $6,606 million (up 23% YoY), and a return to GAAP profitability with 12% operating margin.
View raw filing on EDGAR →Priority Technology Holdings issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, including revenue of $262.3 million (9.4% YoY growth), net income of $9.9 million, diluted EPS of $0.12, and adjusted EBITDA of $59.4 million, along with full-year 2026 guidance. The disclosure includes a scheduled earnings conference call and webcast for the same date.
View raw filing on EDGAR →Airship AI Holdings issued a press release announcing its financial and operational results for Q2 2026 (quarter ended June 30, 2026), reporting net revenues of $4.12 million (92% YoY increase), gross profit of $3.09 million (102% YoY increase), and a net loss of $2.4 million.
View raw filing on EDGAR →The filing discloses FHLBNY's "Second Quarter 2026 Operating Highlights," including $153.3 million in net income for Q2, $128 billion in funding to members (up $35 billion from year-end 2025), and $27.5 million allocated to affordable housing initiatives. While presented as a President's Report rather than a formal earnings press release, the core disclosure is quarterly financial results and operational metrics material to shareholders' assessment of the institution's performance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states "Cronos Group Inc. (the 'Company') issued a press release announcing its financial results for its second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The exhibit contains consolidated financial results showing net revenue of $53.0 million (up 58% YoY), gross profit of $28.5 million (up 96% YoY), and Adjusted EBITDA of $13.1 million (up 675% YoY), along with detailed business performance metrics and brand updates.
View raw filing on EDGAR →Hertz Global Holdings issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $2.4 billion (up 10% YoY), GAAP net income of $64 million, and Adjusted Corporate EBITDA of $81 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, which is the typical format for earnings disclosures and material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (period ending June 30, 2026) disclosed via press release on August 6, 2026. The filing reports comprehensive financial results including GMV of $1.3 billion (up 37.9% YoY), Total Revenue of $149.7 million (up 51.7% YoY), Net Income of $40.8 million (up 47.7% YoY), and updated FY2026 guidance raising Adjusted Net Income to $185.0 million. The disclosure is material to investors as it presents quarterly operating results, key metrics, and forward guidance.
View raw filing on EDGAR →US Foods disclosed its financial results for the fiscal second quarter ended June 27, 2026 via a press release attached as Exhibit 99.1. The disclosure includes key metrics such as net sales growth of 4.5% to $10.5 billion, net income growth of 22.8% to $275 million, diluted EPS of $1.24, and adjusted EBITDA growth of 10.2% to a record $604 million. This is a standard quarterly earnings release with comprehensive financial results and forward guidance, clearly falling under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →This is a clear earnings release disclosing Immunocore's Q2 2026 financial results, including net product revenues of $115.9 million (18% YoY growth), R&D and SG&A expenses, net loss of $0.8 million, and cash position of $880.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the Company "issued a press release announcing its financial results for the second quarter ended June 30, 2026." This is a material disclosure affecting investor assessment of the registrant's financial performance and operational progress.
View raw filing on EDGAR →The Trade Desk issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, with detailed GAAP and non-GAAP financial metrics (revenue of $715 million, net income of $64 million, diluted EPS of $0.14), business highlights, and forward guidance for Q3 2026. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →Acushnet Holdings Corp. issued a press release on August 6, 2026 announcing quarterly and year-to-date financial results for the period ended June 30, 2026. The disclosure includes detailed net sales figures ($820.0 million for Q2, up 13.8% YoY), net income ($124.8 million, up 65.1% YoY), and Adjusted EBITDA ($208.6 million, up 45.8% YoY), along with updated full-year 2026 guidance. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three and six month periods ended June 30, 2026) issued on August 5, 2026. The Item 2.02 disclosure explicitly states the company "issued a press release...announcing its financial results for the three and six month periods ended June 30, 2026," with the full earnings release attached as Exhibit 99.1. The release includes detailed financial results (net interest income, provision for credit losses, net loss, balance sheet metrics, book value per share) and is material to investors assessing the registrant's financial condition.
View raw filing on EDGAR →Unusual Machines, Inc. disclosed Q2 2026 financial results, including revenue of $16.7 million (687% YoY growth), gross margin of 34.7%, operating loss of $7.8 million, and net loss of $7.8 million ($0.16 per share), along with a shareholder letter from CEO Allan Evans and announcement of a conference call to discuss results.
View raw filing on EDGAR →Applied Optoelectronics issued a press release on August 6, 2026 disclosing financial results for Q2 2026 ended June 30, 2026. The disclosure includes GAAP revenue of $191.9 million (up 86% YoY), gross margin, net loss, and non-GAAP profitability metrics, along with Q3 2026 guidance. This is a standard earnings release attached as Exhibit 99.1 under Item 2.02, and the results are material to investors as they show record revenue for the fifth consecutive quarter and a return to non-GAAP profitability.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Q2 2026 financial results for Establishment Labs Holdings Inc. The filing explicitly states in Item 2.02 that the company "issued a press release announcing the Company's financial results for the three and six months ended June 30, 2026 and recent corporate highlights," with the press release furnished as Exhibit 99.1. The disclosure includes revenue of $67.5 million (up 31.7% YoY), gross margin of 70.6%, and raised full-year guidance to $269-271 million, all material metrics for investor assessment.
View raw filing on EDGAR →Praxis Precision Medicines reported Q2 2026 financial results, including R&D expenses of $69.4M, G&A expenses of $27.5M, a net loss of $83.7M, and a cash position of $1.4B as of June 30, 2026. The disclosure includes operational highlights and anticipated milestones for the company's drug development programs, providing investors with visibility into the company's financial performance and cash runway into 2028.
View raw filing on EDGAR →Kinetik issued a press release on August 5, 2026 announcing financial and operating results for the fiscal quarter ended June 30, 2026, disclosing net income of $123.1 million and $118.0 million for the three and six months ended June 30, 2026, respectively, along with Adjusted EBITDA, Distributable Cash Flow, and Free Cash Flow metrics. The company also raised full year 2026 Adjusted EBITDA guidance to $1.04–$1.1 billion. This is a standard quarterly earnings release with material financial results and forward guidance that would affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →Once Upon a Farm issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing net sales of $85.4 million (42.3% YoY growth), net loss of $5.0 million, and raising full-year 2026 guidance for both net sales ($327–$335 million) and Adjusted EBITDA ($3–$4.5 million). This is a classic earnings release disclosure under Item 2.02, furnished with the press release as Exhibit 99.1 and accompanied by detailed financial statements and management commentary.
View raw filing on EDGAR →The filing discloses quarterly financial results for Q2 2026 via a press release attached as Exhibit 99.1. The press release reports net revenue of $17.2 million (56% growth), gross margin of 78.3%, and raises full-year 2026 guidance to $67–69 million. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and growth trajectory.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 6, 2026. The Item 2.02 disclosure explicitly states "Optimum Communications, Inc. announced its financial results for the quarter ended June 30, 2026" with a press release attached as Exhibit 99.1. The exhibit contains comprehensive financial results including revenue ($2.02 billion), net loss ($291.8 million), Adjusted EBITDA ($785.7 million), and detailed operational metrics. This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →Funko disclosed consolidated financial results for Q2 2026 (three and six months ended June 30, 2026) via press release, reporting net sales of $207.7 million (7% growth), record gross margin of 56.6%, net income of $15.4 million ($0.27 per diluted share), and raising full-year Adjusted EBITDA guidance to $100M–$110M.
View raw filing on EDGAR →Core Natural Resources issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, disclosing net income of $126.5 million ($2.51 per diluted share), adjusted EBITDA of $323.6 million, and free cash flow of $148 million, along with comprehensive operational metrics, segment performance, and forward guidance.
View raw filing on EDGAR →The 6-K body explicitly states it "contains: Exhibit 1: Loma Negra Earnings Release 2Q26," indicating disclosure of second-quarter 2026 financial results. Earnings releases are material events that affect investor assessment of the registrant's financial performance and are commonly furnished as exhibits to Form 6-K by foreign private issuers.
View raw filing on EDGAR →Burford Capital issued a press release and detailed presentation on August 6, 2026, announcing its unaudited financial results for the three and six months ended June 30, 2026 (2Q26 and YTD26). The disclosure includes quarterly financial results, cash position ($733 million), and portfolio performance commentary from the CEO. This is a standard earnings release disclosure under Item 2.02, with exhibits 99.1 and 99.2 containing the press release and presentation respectively.
View raw filing on EDGAR →This is a clear earnings release disclosing Denali Therapeutics' second quarter 2026 financial results. The Item 2.02 filing explicitly states "On August 6, 2026, Denali Therapeutics Inc. (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026." The press release (Exhibit 99.1) reports Q2 2026 net product revenue of $3.6 million, R&D expenses of $97.0 million, SG&A expenses of $36.3 million, and a net loss of $127.6 million, along with cash position and business highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →Zentalis Pharmaceuticals reported second quarter 2026 financial results and business updates, including cash position of $174.6 million, R&D expenses of $35.2 million, and G&A expenses of $9.2 million, along with material clinical milestones including DENALI enrollment completion, FDA Type D meeting alignment, and ASPENOVA Phase 3 first patient dosed.
View raw filing on EDGAR →Frontdoor issued a press release on August 6, 2026, announcing its financial results for the fiscal quarter ended June 30, 2026. The disclosure includes detailed quarterly financial metrics (revenue of $645 million, net income of $125 million, EPS of $1.76), year-to-date performance, and raised full-year 2026 guidance for revenue and Adjusted EBITDA. This is a standard quarterly earnings release attached as Exhibit 99.1 and disclosed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →i3 Verticals issued a press release on August 6, 2026, announcing financial results for the three and nine months ended June 30, 2026, including revenue of $53.1 million (up 2.2% YoY), net income from continuing operations of $5.9 million, adjusted EBITDA of $13.3 million, diluted EPS, and revised fiscal 2026 guidance.
View raw filing on EDGAR →